Akero Therapeutics Stock Price, News & Analysis

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company focused on treatments for non-alcoholic steatohepatitis (NASH) and metabolic disorders, will present at Evercore’s 3rd Annual HealthCONx virtual conference. The fireside chat is scheduled for 11:20 a.m. ET on December 3, 2020. A live webcast and a replay will be accessible on the company's investor relations website for 30 days post-event. Akero's lead candidate, Efruxifermin (formerly AKR-001), is currently in a Phase 2a clinical trial, aiming to combat the NASH epidemic.

Akero Therapeutics (Nasdaq: AKRO) presented new data from its Phase 2a BALANCED study at The Liver Meeting®, highlighting efruxifermin (EFX) as a promising monotherapy for non-alcoholic steatohepatitis (NASH). The study revealed significant reductions in liver fat, with 100% of patients in the 50mg EFX group achieving over 50% relative reduction. Additionally, 50% of patients with fibrosis stage F2 or F3 experienced a two-stage improvement. EFX, showing positive effects on glycemic control, is expected to enter a Phase 2b/3 trial in 2021, supported by EMA’s PRIME designation.

Akero Therapeutics (Nasdaq: AKRO) reported its Q3 2020 financial results, highlighting significant advancements in its NASH treatment, efruxifermin (EFX).

The company raised over $216 million through an equity offering and received FDA feedback facilitating an adaptive Phase 2b/3 clinical trial. EFX also gained PRIME designation from EMA, underscoring its potential in the NASH market.

Cash reserves stood at $291.9 million as of September 30, 2020, while operating expenses increased to $21.5 million for Q3 due to higher research and development costs.

Akero Therapeutics (Nasdaq: AKRO), a biotechnology company focused on treatments for non-alcoholic steatohepatitis (NASH), will present at two investor conferences in November 2020. The 29th Annual Credit Suisse Healthcare Conference is scheduled for November 9 at 1:15 PM EST, and the Jefferies Global Healthcare Conference on November 17 at 1:45 PM EST. Live webcasts will be available on their website, with archived replays following the presentations. Akero is dedicated to reversing the NASH epidemic through innovative medicines, particularly their lead candidate, efruxifermin.

Akero Therapeutics (Nasdaq: AKRO) announced that the European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to efruxifermin (EFX), an investigational treatment for non-alcoholic steatohepatitis (NASH). This designation follows promising results from the Phase 2a BALANCED study, where 48% of patients showed significant improvement. The PRIME program aims to expedite the development of EFX as it addresses unmet medical needs in NASH, which affects millions globally.

Akero Therapeutics (Nasdaq: AKRO) announced that an abstract detailing analyses from the Phase 2a BALANCED study of efruxifermin (EFX) has been accepted for presentation at The Liver Meeting Digital Experience 2020, scheduled for November 13-16. The presentation will highlight significant reductions in liver fat and ALT levels among NASH patients after 16 weeks of EFX treatment. NASH affects around 17 million Americans, highlighting the potential market need and impact of EFX in treating this condition. The next Phase 2b/3 pivotal study is set to begin in early 2021.

Akero Therapeutics (Nasdaq: AKRO) has completed enrollment of a cohort of 30 NASH patients with compensated cirrhosis (F4), Child-Pugh Class A, for a trial assessing safety and tolerability of efruxifermin (EFX). This randomized 16-week trial has a primary focus on patients at high risk of liver complications. Akero expects to report results in the first half of 2021. NASH, affecting 17 million Americans, can lead to serious liver conditions. EFX, designed to enhance metabolic balance, has shown potential in addressing NASH-related health issues.

Akero Therapeutics (Nasdaq: AKRO) announced that CEO Andrew Cheng will present virtually at the H.C. Wainwright 4th Annual NASH Conference on October 5, 2020, at 12:00 p.m. E.T. The presentation will be accessible via a live webcast on the company's website, www.akerotx.com. Akero focuses on developing treatments for non-alcoholic steatohepatitis (NASH) with its lead product candidate, AKR-001, currently in a Phase 2a clinical trial. For more information, visit Akero's website.

Akero Therapeutics (Nasdaq: AKRO) announced FDA approval for an adaptive Phase 2b/3 trial design for its lead candidate, efruxifermin (EFX), targeting non-alcoholic steatohepatitis (NASH). This innovative study will assess two EFX doses over 24 weeks before selecting one for Phase 3 evaluation, set to commence in the first half of 2021. The FDA's guidance follows positive histological data from the BALANCED study, enhancing confidence in EFX's potential as a treatment. Akero aims to reverse the NASH epidemic, which affects approximately 17 million Americans.